File downloaded on 2026-11-18
Source URL: https://medicines.health.europa.eu/veterinary/en/600000036907

Cardisure Flavoured 1.25 mg Tablets for Dogs

Authorised

- Pimobendan

Product identification

Medicine name:
Cardisure Flavoured 1.25 mg Tablets for Dogs

Active substance:
Pimobendan

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Pimobendan
1.25 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QC01CE90

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Denmark

Available in:
Denmark

Package description:
10 blisters per carton, 10 tablets per blister (Aluminium - PVC,PE,PVDC blister)
10 blisters per carton, 10 tablets per blister (Aluminium - Aluminium blister)
2 blisters per carton, 10 tablets per blister (Aluminium - PVC,PE,PVDC blister)
2 blisters per carton, 10 tablets per blister (Aluminium - Aluminium blister)
25 blisters per carton, 10 tablets per blister (Aluminium - Aluminium blister)
25 blisters per carton, 10 tablets per blister (Aluminium - PVC,PE,PVDC blister)
5 blisters per carton, 10 tablets per blister (Aluminium - PVC,PE,PVDC blister)
5 blisters per carton, 10 tablets per blister (Aluminium - Aluminium blister)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Dechra Regulatory B.V.

Marketing authorisation date:
27/07/2011

Manufacturing sites for batch release:
Dales Pharmaceuticals Limited
Eurovet Animal Health B.V.
Genera d.d.

Responsible authority:
Danish Medicines Agency

Authorisation number:
47108

Date of authorisation status change:
27/07/2011

Reference member state:
Netherlands

Procedure number:
NL/V/0280/001

Concerned member states:
Austria Belgium Denmark Finland France Germany Greece Ireland Italy Luxembourg Norway Poland Portugal Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)
Published on: 16/06/2022

Updated on: 14/03/2026

Download

Combined File of all Documents

107727 PAR.pdf